Antibiotic resistance

is a global threat

Classical new antibiotics lose their effectiveness within 5-7 years because bacteria adapt to them very quickly

So, healthcare needs new – "investment-attractive" antibiotics

  • To which resistance DOES NOT form over the time
  • Or resistance might be formed, but NOT faster than 20 years - i.e. while the drug-patent is in effect
  • Effective against infections that would cause those 10 million deaths per year
  • With broad spectrum of antimicrobial activity

Antimicrobial peptides are the base for the development of new drugs and they solve all the problems of "classic" antibiotics:

  • Produced by living cells (including human) to fight cancer and infections
  • More that 3000 natural peptides discovered
  • High activity
  • Low immunogenicity
  • Good biocompatibility

Antimicrobial peptides "cut" bacteria, which leads to their death in 20 min after exposition…

The arrows indicate where the peptide cuts the bacterial cell. Some peptides can do the same with cancer cells. This mechanism of action determines why resistance is not formed to antimicrobial peptides (or is formed, but very slowly).


antimicrobial/anticancer peptides of natural origin might have some disadvantages

Poor stability
Toxic and/or hemolytic effect
«Narrow» spectrum of activity
Bad pharmacokinetics

PeptiGen Platform

We have developed and tested method for the de novo"design" of new peptides using artificial intelligence (AI) and bioinformatic tools

Our «PeptiGen» platform generates new peptides that have

  • Broad spectrum of antimicrobial action
  • Low toxicity and immunogenicity
  • Effective against infections that will cause 10 million deaths a year
  • Pronounced effect at low doses in animal infection model


drug development platform


on the example of new peptide antibiotics

Efficacy of some the our AI-generated peptides in experimental carbapenem-resistant K. pneumoniae sepsis

After a single injection of only 100 microgram (!) lethality is reduced by:

  • 50% for PEP-137
  • 70% for PEP-36

Novel Antimicrobial Peptides Designed Using a Recurrent Neural Network Reduce Mortality in Experimental Sepsis

Bolatchiev Albert

2022. Antibiotics 11, no. 3: 411

Our product

novel peptide-based antibiotics + technology for the development of new patentable peptide compounds

Antibiotics market

Key market drivers

  • Rising number of infectious diseases
  • Global population growth
  • Increasing proportion of infections resistant to antibiotics
  • Loss of "classic" antibiotics
  • Largest market size – Asia
  • Today, every year, 1.2 million people die because they have an antibiotic-resistant infection. By the middle of the 21st century, this figure will reach 10 million annual deaths. We must save these lives
  • Why we should invest in antibiotics — REPAIR Fund

Technologies and Global Markets

2021, BCC Reports

We are looking for investments

So, we have the proof-of-concept –

our platform can generate novel peptides with pharmacological activity and highly effective in animal models

Intellectual property

Intellectual property

Lead optimization

Lead optimization

Pre-clinical studies

Pre-clinical studies


these are modified derivatives of the peptides PEP-36 and PEP-137, which reduced mortality by 70% and 50%, respectively, in septic mice. These compounds have a pronounced activity against carbapenem-resistant strains of gram-negative bacteria.


this is a modified PEP-38, with a pronounced antibacterial activity against carbapenem-resistant strains of Klebsiella and Pseudomonas aeruginosa.

AVP-81 и AVP-84

compounds with potential for the treatment of viral infections caused by SARS-Cov-2 and/or other coronaviruses. In vitro studies are currently being carried out.


was originally de novo developed as an antiviral compound, but it had a potentially significant antitumor effect. In vitro studies are currently being carried out.

Leave your phone number and our specialists will contact you within 30 minutes to provide more complete information on your questions!

Call us by phone:+7 928 820 55 51
Write to us by email:info@peptigen.com